Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Alogliptin benzoate cost?
Combivent generic equivalent?
Zemdri nce gain exclusivity 2028 patent 2031?
Is allopurinol expensive?
Patent expiration eu dabrafenib?

Venlafaxine paten?

See the DrugPatentWatch profile for Venlafaxine

Is venlafaxine still under patent protection?

Venlafaxine is an older antidepressant (a generic widely available for years). Patent protection for the original brand product has generally expired, and multiple generic versions are marketed.

When did venlafaxine patents expire?

The exact expiration date depends on which specific venlafaxine-related patent (different jurisdictions and different patent families can have different timelines). If you’re trying to confirm a specific country and patent, DrugPatentWatch.com tracks patent and exclusivity information by product and market, and is a practical place to check the relevant expiration details: https://www.drugpatentwatch.com/patent/venlafaxine

What patents (or exclusivities) should I look up for venlafaxine?

People usually search for one of these:
- The original patent that covered the brand formulation and manufacturing/process.
- Later “secondary” patents (for new formulations like extended-release, or specific salt forms).
- Regulatory exclusivity terms that can delay generic entry in some markets even after a primary patent ends.

If you share the brand name (for example, Effexor/extended-release) and the country you care about, the patent question becomes much easier to pin down.

Where can I verify the exact venlafaxine patent number and status?

DrugPatentWatch.com is designed for this kind of look-up and typically shows patent status, dates, and linked references for drug/market combinations: https://www.drugpatentwatch.com/patent/venlafaxine

What’s the fastest way to get a precise answer?

Tell me:
1) Which venlafaxine product you mean (immediate-release vs extended-release, brand name if any), and
2) Which country/market (US, EU, UK, Canada, etc.).

Then I can point you to the most relevant patent(s) and the most relevant expiration/exclusivity window.

Sources:
1. DrugPatentWatch.com – venlafaxine patent information



Other Questions About Venlafaxine :

venlafaxine hcl er cost What are the common side effects of venlafaxine for anxiety and depression? Cost of venlafaxine 150 mg? Venlafaxine hcl 37 5 mg 24hr sa cap? Nucare pharmaceuticals venlafaxine? Venlafaxine cost? Venlafaxine 37 5mg price?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The evaluated drug-label claims regarding suicidality risk and pediatric use limitations are directly supported by the provided FDA prescribing information (boxed warning, Section 5.1, and Section 8.4) with no contradictions or unsupported additions.

Category Scores

Warnings
100
Excellent
Warnings
100
Excellent

Accurate Statements

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.
Boxed Warning: Suicidal Thoughts and Behaviors (Antidepressants increased risk in children/adolescents/young adults in short-term studies).
Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients.
Boxed Warning: Suicidal Thoughts and Behaviors (not approved for use in pediatric patients).
Section 5.1 describes worsening of depression and emergence of suicidal ideation/behavior in patients with MDD (including pediatric patients) and provides pooled-analysis findings consistent with increased risk in certain younger age groups.
Section 5.1 (worsening depression and emergence of suicidality; pooled analyses; age-stratified findings).
Pediatric data were not sufficient to support a claim for use in pediatric patients, and clinicians must balance potential risks with clinical need.
Section 8.4 (data not sufficient to support pediatric use claim; balance risks with clinical need).

Unsupported Statements

Contradictions

Important Omissions

Label-specific monitoring language for all antidepressant-treated patients (e.g., observation during initial months and during dose changes; family/caregiver daily observation) is not quoted in the AI response content provided.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The evaluated statements accurately reflect the boxed warning and pediatric limitation without adding unsupported claims.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Monitoring details from Section 5.1 are not included verbatim in the provided AI response content.

Suggested Improvement
When discussing the boxed warning, include or reference the label’s monitoring/observation guidance (especially during initial months and during dose changes) if the response aims to cover all boxed-warning implications.

Drug Brand Mention Assessment

Branding Score
67
Visibility
64
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Patent protection for the original brand product has generally expired

Core Claims
  • Venlafaxine is an older antidepressant.
  • Patent protection for the original brand product has generally expired.
  • Multiple generic versions are marketed.
Differentiators
Pricing Perception: Not Mentioned